Algeta mounts challenge to antibody-drug conjugates

Algeta ASA is accelerating its bid to produce an alternative platform to the antibody-drug conjugate with the launch of a new programme of radionuclides linked to monoclonal antibodies. The latest programme is directed at haematological cancers.